Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine The costs and benefits of senotherapeutics for human health The Lancet Healthy Longevity
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols
product description
Why choose thelockerguy wholesale?
Show More
foxo4-dri senolytic human trial The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI